Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vertex Gets FDA Acceptance for Vanzacaftor/Tezacaftor/Deutivacaftor for Cystic Fibrosis
Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Brand Name : VX-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2024
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Brand Name : VX-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 05, 2024
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vertex Start Phase 3 Development Program for New Once-Daily Triple Combo Regimen
Details : The combination of VX-121/tezacaftor/VX-561 was first identified as having potential for increased efficacy based on its ability to drive higher levels of chloride transport compared to TRIKAFTA (elexacaftor/tezacaftor/ivacaftor /ivacaftor) in human bron...
Brand Name : VX-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 28, 2021
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Deutivacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Vertex
Deal Size : $250.0 million
Deal Type : Agreement
Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million
Details : VX-561 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis.
Brand Name : VX-561
Molecule Type : Small molecule
Upfront Cash : $160.0 million
May 17, 2021
Lead Product(s) : Deutivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Vertex
Deal Size : $250.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?